Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40
- Resource Type
- Article
- Source
- In
Ophthalmology August 2024 131(8):967-974 - Subject
- Language
- ISSN
- 0161-6420